share_log

Chardan Capital Reiterates Buy on Achilles Therapeutics, Maintains $11 Price Target

Benzinga ·  Aug 7, 2023 05:36

Chardan Capital analyst Geulah Livshits reiterates Achilles Therapeutics (NASDAQ:ACHL) with a Buy and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment